A precursor to the gastrointestinal hormone secretin has been isolated. The starting material for the purification of the precursor was a peptide fraction purified from pig intestinal extracts, containing peptides with a molecular weight higber than that of secretin. The purification could be followed by measurement ofsecretin bioactivity (alkali secreted in the pancreatic juice of anesthetized cat). Sequence analysis of the isolated secretin precursor revealed a 71-amino acid residue polypeptide that contained the sequence of secretin N terminally, followed by a Gly-Lys-Arg sequence and a Cterminal extension of 41-amino acid residues. With the exception of an arginine residue, which occurs directly after the Gly-Lys-Arg sequence, the remalnder of the C-terminal residues in this precursor are identical to the 40 C-terminal residues predicted by the recently described cDNA sequence for porcine preprosecretin. Compared to the deduced preprosecretin sequence, a stretch of 32 amino acid residues directly following the Gly-Lys-Arg sequence is missing in the now purified secretin precursor. This implies that differential splicing may occur when the secretin gene transcript is processed to mRNA.
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After its discovery in 1902 by Bayliss and Starling (1) , almost 60 years elapsed before secretin (the porcine form of it) was isolated (2) and another 10 years elapsed before its primary structure was finally deduced (3) . Pig secretin is a 27-amino acid residue peptide with a C-terminal valine amide. Cow and guinea pig secretin were found to be identical to that of the pig form (4, 46) , whereas the human (5), dog (6) , rat (7) , and rabbit (8) secretin all differ slightly from each-other and from the porcine/bovine/guinea pig form. Chicken secretin is different from all the mammalian forms. However, it is, like the others, composed of 27-amino acid residues and is C-terminally amidated (9) . The main action of secretin is to stimulate secretion of bicarbonate-rich pancreatic juice, but it also exerts other actions (10) . Although secretin immunoreactivity, as well as bioactivity, has been reported in the central nervous system (11) (12) (13) , secretin has so far only been isolated from intestine, where it is known to be localized in endocrine cells, called S cells, in the duodenum and upper jejunum (14, 15) .
Until recently, the structure of the secretin precursor was unknown. This was probably due to secretin being composed of amino acids with degenerated codons, making it difficult to synthesize appropriate probes. However, using the polymerase chain reaction technique, Kopin et al.. (16) were able to isolate cDNA encoding pig and rat preprosecretin. The deduced amino acid sequence of the porcine secretin precursor (16) includes a signal peptide, an N-terminal flanking peptide ('10 amino acid residues), secretin, a Gly-Lys-Arg cleavage and amridation sequence, and a 72-amino acid residue C-terminal flanking peptide.
Because of the difficulties in isolating the secretin precursor by conventional cDNA techniques and to investigate the biosynthetic pathway of secretin, we decided to isolate a larger prosecretin protein. We knew from earlier studies on C-terminal extended forms of secretin,-secretin-Gly (17) and secretin-Gly-Lys-Arg (18) , that a free C-terminal valine amide is not required for biological activity in the secretin bioassay measuring alkali secreted in the pancreatic juice of anesthetized cat. On the other hand, a free N-terminal histidine seems essential for appreciable bioactivity (19) . When high molecular weight side fractions from the purification of secretin from pig upper intestine were investigated for secretin bioactivity, activity could be found-in one of these fractions. The present paper reports the isolation and characterization of a secretin precursor that is C-tierminally extended.
MATERIALS AND METHODS
Preparation of Starting Material. Extraction of pig. intestines (upper part) was carried out as described (20) . Briefly, batches (=1000 kg) of rinsed, boiled (10 min in boiling water), frozen, and minced pig intestines were extracted in 3% acetic acid at 0WC-100C overnight. Extracted peptides were collected from the filtrate on alginic acid; eluted with 0.2 M HC1, and NaCl precipitated, resulting in a concentrate of thermostable intestinal peptides (CTIP). The (24) and in a Milligen Prosequencer 6600 instrument using carboxyl group coupling of the peptide to an arylamine filter.
RESULTS
Isolation of the Secretin Precursor. In the search for larger secretin precursors, high molecular weight side fractions from the purification of secretin were tested for secretin bioactivity in the secretin bioassay. In Table 1 , the preparations of CTIP and CTIP-1 are common for the purification of secretin and the secretin precursor. In the third purification Data are from 16,500 kg of pig intestine (originating from -230,000 animals). Pure pig secretin used as standard has an activity of 3500 units/mg. The values of secretin bioactivity are, especially in the earlier steps, approximate (i) due to the crudeness of the material, and (ii) because they were calculated from single activity measurements. ND, not determined; RP, reverse phase.
step, a Sephadex G-25 fine chromatography in 0.2 M acetic acid on a column (35 x 135 cm), secretin activity was detected in fraction 2 and in fractions 4-6. The activity in the last three fractions corresponds to secretin, while the activity found in fraction 2, which only corresponds to a few percent of the total activity, originates from material with a higher molecular weight than secretin. This material was used as the starting material for the purification of the secretin precursor. The purification is outlined in Table 1 and after each purification step the fractions were tested for bioactivity in the secretin bioassay.
The starting material, Sephadex fraction 2, was methanol extracted. All secretin activity was retained in a fraction that was methanol soluble at acidic pH but was insoluble at neutral pH. This fraction was further purified by two consecutive CM-cellulose chromatographies. In the first chromatographic procedure, the peptides were eluted with a NaCl gradient (0-0.2 M NaCl) in a phosphate buffer (pH 6.4). Most of the secretin activity was found in fraction 5 (eluted with 0.015-0.025 M NaCl), which was further chromatographed on a second CM-cellulose column at pH 8 and eluted with increasing concentrations of ammonium bicarbonate. Secretin activity was found in two fractions-10 and 11. These fractions were subjected separately to preparative reversephase HPLC using identical separation conditions for the two fractions. The secretin activity was found to elute at the same position in the chromatograms of both fractions 10 and 11. It was concluded that these two fractions contained the same bioactive peptide and, after the reverse-phase chromatography, the active fractions were pooled together. Fig. 1 shows the active reverse-phase fraction chromatographed on a CM HPLC column in an acetic acid/ammonium acetate system. All the secretin activity was found in fraction 6, which was essentially pure as shown in the last purification step, a reverse-phase chromatography (Fig. 2) .
The secretin activity of the purified secretin precursor compared to a secretin standard is outlined in instrument. The sequence of the entire fragment could be determined this way with the exception of position 38 (position 67 in the whole peptide), which was unclear but was identified as a serine residue based on the amino acid composition of the fragment. Comparison to the published preprosecretin sequence (16) also predicts serine at this position. The deduced sequence of the entire secretin precursor is shown in Fig. 3 .
DISCUSSION
A secretin precursor has been isolated from pig upper intestine. This precursor consists of 71 amino acid residues. It includes secretin at the N terminus, beginning with the N-terminal histidine of secretin, and has a C-terminal extension of 44 residues, including the cleavage and amidation signal Gly-Lys-Arg directly following the secretin sequence.
The amino acid sequences of pig and rat preprosecretin were recently deduced from isolated cDNAs from the two species (16) . The porcine secretin precursor consists of a signal peptide, a short N-terminal flanking peptide (-10 residues), the secretin sequence, a Gly-Lys-Arg cleavage and amidation site, and a 72-residue C-terminal flanking peptide. The 44-residue C-terminal extension of the now isolated secretin precursor corresponds to the Gly-Lys-Arg sequence, an additional arginine residue, and the 40 C-terminal amino acids of the published porcine preprosecretin. The isolated precursor thus lacks a stretch of 32 amino acid residues directly following the Gly-Lys-Arg sequence in the preprosecretin sequence deduced from pig cDNA. The most probable explanation for this is that the isolated secretin precursor originates from a mRNA species different from the mRNA used by Kopin et al. (16) for cDNA construction. This implies a differential splicing mechanism for the secretin mRNA. The arginine residue at position 31 in the isolated secretin precursor would then arise at a splicing site as a result of the splicing event. According to the consensus sequences for splice junctions (25) , the exon donor site is usually AG, which is also the case for the 2 nucleotides following the Gly-Lys-Arg codons in the preprosecretin cDNA. At the acceptor site, G(G/T) is a common sequence; in the preprosecretin cDNA, GA is found at the exon side of the putative splicing acceptor site. The codon that arises after the splicing event (AGG) encodes arginine and the remaining A at the splicing acceptor site corresponds to the first nucleotide in the methionine codon following the arginine codon (Fig. 4) .
Differential splicing has been reported-e.g., for calcitonin-calcitonin gene-related peptide (26) , the tachykinins (27) (28) (29) , gastrin-releasing peptide (30, 31) , and the kininogens (32) . In the glucagon-secretin family of peptides, all precursor protein sequences are now known. There is no evidence for differential splicing reported for the other members of the family [i.e., glucagon (33, 34) , vasoactive intestinal peptide (VIP) peptide with N-terminal histidine, C-terminal isoleucine amide (PHI) (35) , gastric inhibitory peptide (36), growth hormone-releasing factor (37, 38) , and pituitary adenylate cyclase-activating peptide (39) ]. This does not rule out the possibility that such mechanisms occur, since the isolated cDNAs originate from single mRNA species and other mRNAs may thus be present but are not detected. In the case of glucagon and VIP/PHI, the genes have also been cloned. Preproglucagon is encoded by six exons (40, 41) and the VIP/PHI precursor is encoded by five exons (42, 43) . In both cases, each functional domain of the precursor is encoded by a separate exon. In theory, these exons could be spliced in several ways, giving rise to different mRNA transcripts.
The structure of the isolated secretin precursor also suggests that during its processing the removal of the N-terminal flanking peptide (a cleavage at a single arginine residue) is the first processing event of prosecretin. It occurs before the C-terminal extension of the precursor is cleaved off to create the earlier isolated proform of secretin-secretin-Gly-LysArg (18)-which in turn is the substrate for some carboxypeptidase B-like enzyme and the amidation enzyme petidylglycine a-amidating monooxygenase (44, 45) .
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